immunoglobulin single variable domain, tnfalfa receptor type 1 antagonist, use of a tnfr1 domain or antagonist, recombinant nucleic acid, vector, host cell, and pharmaceutical composition

摘要

immunoglobulin single variable domain, tnfalfa receptor type 1 antagonist, use of a tnfr1 domain or antagonist, recombinant nucleic acid, vector, host cell, and pharmaceutical composition the invention relates to anti-tnfr1 polypeptides and single antibody variable domains (dabs) that are resistant to degradation by a protease, as well as antagonists comprising them. polypeptides, dabs and antagonists are useful for therapy and / or prophylaxis, which are likely to find proteases when administered to a patient, for example for pulmonary administration, oral administration, dispensing to the lung and dispensing to a patient's gastrointestinal tract, as well as to treat inflammatory diseases, such as arthritis or chronic obstructive pulmonary disease (copd).